原发性侧索硬化:荷兰自然史研究对诊断标准的启示
荷兰一项长期随访队列研究纳入86例上运动神经元综合征患者,验证2020年PLS共识诊断标准。结果显示14%的PLS患者初始诊断改变,49%单区域上运动神经元症状者进展为PLS;病程短于4年者生存期更短, probable PLS组33%转化为ALS。建议将PLS诊断推迟至症状出现4年后,并按区域受累分类。
要点
- PLS诊断应推迟至症状出现4年后,因病程短与ALS转化率高和生存期短相关。
- 单区域上运动神经元症状者中49%进展为PLS,需密切监测。
- probable PLS患者33%转化为ALS,转化者ALSFRS斜率更陡且症状持续时间更短。
核心结论
- PLS诊断应推迟至症状出现4年后,因较短病程与更高的ALS转化率和更短生存期相关。
- 按区域受累分类可能有助于更有效地监测上运动神经元综合征患者。
研究设计与样本
- 长期随访队列验证研究,纳入86例上运动神经元综合征且病程≥6个月的成人患者。
- 患者在基线(T1)、3年(T2)及尽可能13年后(T3)评估,诊断分类遵循2020年PLS共识标准。
主要发现
- 86例患者中43例在基线符合PLS共识标准(6例 probable,37例 definite)。
- 14%的PLS患者初始诊断发生改变,49%单区域上运动神经元症状者进展为PLS。
- 7例发展为ALS,7例修订为遗传性痉挛性截瘫(HSP)。
- probable PLS组中33%转化为ALS,转化者ALSFRS斜率更陡(p=0.023)且纳入时症状持续时间更短(p<0.001)。
- 出现腿部症状的患者中,29%在T2至T3期间诊断修订。
关键数值与推荐
- 采用2020年PLS共识标准进行诊断分类。
- 引入4年最小病程诊断PLS并按受累区域分类后,86%的PLS诊断保持在PLS类别,5%转为ALS(慢变异型),9%转为HSP。
- 基线症状局限于手臂和腿部或仅腿部者生存期最长,其次为基线有延髓受累者,病程6个月至4年者生存期最短。
临床怎么用
- 对疑似PLS患者,建议在症状出现4年后再确诊,以降低误诊风险。
- 根据区域受累分类(如延髓、腿部等)进行随访监测,关注ALS转化迹象。
- 对病程短于4年的患者,应更密切监测病情进展和生存期。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Primary lateral sclerosis (PLS) is a rare disease characterized by upper motor neuron (UMN) degeneration. We aimed to elucidate the natural history in patients with UMN syndromes suggestive of PLS and validate the most recent diagnostic (consensus) criteria. METHODS: A validation study of a long-term follow-up cohort was conducted, including adults with UMN syndromes and disease durations ≥6 months. Patients were assessed at baseline (T1), at 3 years (T2), and when possible after 13 years (T3). Diagnostic categorization followed the 2020 PLS consensus criteria. Main outcomes included diagnostic classification at follow-up and survival. RESULTS: The study comprised 86 patients (34 women [40%], mean age 58.9 ± 10.1 years), of whom 43 met the PLS consensus criteria at baseline (6 probable, 37 definite). Eight patients had a disease duration <2 years, and 35 patients presented with UMN symptoms localized to 1 region (1 bulbar, 34 legs). Change of initial diagnosis occurred in 14% of patients with PLS, and 49% of patients presenting with UMN symptoms in 1 region progressed to PLS. Seven patients developed amyotrophic lateral sclerosis (ALS), and for 7 patients, diagnosis was revised to hereditary spastic paraplegia (HSP). Survival was shorter for patients with a disease duration <4 years. In the probable PLS group, 33% converted to ALS. Converters had a steeper Amyotrophic Lateral Sclerosis Functional Rating Scale slope (p = 0.023) and shorter symptom duration (p < 0.001) at inclusion. Of patients presenting with leg symptoms, diagnosis was revised between T2 and T3 in 29%. Introducing a 4-year minimal disease duration for PLS diagnosis and categorization based on regions involved resulted in 86% of PLS diagnoses remaining within the PLS category, 5% transitioning to ALS (slow variant), and 9% to HSP. Survival was longest for patients presenting with symptoms confined to arms and legs or legs only, followed by those with bulbar involvement at baseline, while patients with disease durations between 6 months and 4 years exhibited the shortest survival. DISCUSSION: Our findings suggest that a diagnosis of PLS should be deferred until 4 years after symptom onset because shorter durations correlate with higher ALS conversion rates and shorter survival. Categorization by regional involvement may facilitate more effective monitoring of patients with UMN syndromes.
引用
- de Vries BS, de Boer EMJ, Brugman F, et al. Primary Lateral Sclerosis: Implications for Diagnostic Criteria From a Natural History Study in the Netherlands. Neurology. 2025. PMID: 40388677. doi:10.1212/WNL.0000000000213461
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。